Published in Hepatology on August 01, 2005
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology (2013) 2.03
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol (2006) 1.63
Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther (2011) 1.57
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. Gastroenterol Res Pract (2014) 1.42
Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int (2011) 1.15
A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection. Hepat Mon (2010) 1.13
Non-invasive assessment of liver fibrosis. Ann Gastroenterol (2012) 1.07
Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol (2009) 1.02
Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol (2014) 1.00
Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther (2015) 1.00
Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol (2009) 0.94
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. J Gastroenterol (2011) 0.90
Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol (2007) 0.90
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Diagnostic Accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.90
Liver elastography, comments on EFSUMB elastography guidelines 2013. World J Gastroenterol (2013) 0.89
Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B. Clin Mol Hepatol (2014) 0.88
Non-invasive diagnosis of hepatitis B virus-related cirrhosis. World J Gastroenterol (2014) 0.87
Comparison of liver biopsy and transient elastography based on clinical relevance. Can J Gastroenterol (2008) 0.86
Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection. World J Gastroenterol (2012) 0.86
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol (2016) 0.86
Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One (2013) 0.86
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J (2011) 0.85
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol (2012) 0.85
Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. PLoS One (2015) 0.84
Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol (2012) 0.84
A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension. Liver Int (2009) 0.84
A new metabolism-related index correlates with the degree of liver fibrosis in hepatitis C virus-positive patients. Gastroenterol Res Pract (2015) 0.84
A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. PLoS One (2014) 0.80
Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci (2010) 0.80
A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. Hepat Mon (2013) 0.79
Spleen stiffness correlates with the presence of ascites but not esophageal varices in chronic hepatitis C patients. Biomed Res Int (2013) 0.78
Non-invasive prediction of forthcoming cirrhosis-related complications. World J Gastroenterol (2014) 0.78
A new scoring system for prediction of fibrosis in chronic hepatitis C. Hepat Mon (2011) 0.78
Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol (2015) 0.78
Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. PLoS One (2013) 0.78
Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.78
Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence. World J Gastroenterol (2015) 0.78
Preoperatively staging liver fibrosis using noninvasive method in hepatitis B virus-infected hepatocellular carcinoma patients. Oncotarget (2017) 0.77
Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol (2015) 0.76
Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat (2011) 0.76
Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol (2010) 0.76
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS One (2016) 0.75
Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis. Int J Mol Sci (2016) 0.75
Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. J Clin Exp Hepatol (2012) 0.75
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med (2017) 0.75
Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One (2016) 0.75
Serum NX-DCP as a New Noninvasive Model to Predict Significant Liver Fibrosis in Chronic Hepatitis C. Hepat Mon (2015) 0.75
A novel system for predicting liver histopathology in patients with chronic hepatitis B. Medicine (Baltimore) (2017) 0.75
Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep (Oxf) (2017) 0.75
Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One (2017) 0.75
Utility of Electronic Medical record-based Fibrosis Scores in Predicting Advanced Cirrhosis in Patients with Hepatitic C Virus Infection. J Transl Int Med (2017) 0.75
Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis. PLoS One (2017) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Liver biopsy. Hepatology (2009) 7.61
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med (2002) 6.64
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr (2008) 5.01
Alcoholic hepatitis. N Engl J Med (2009) 4.98
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
The prevalence of celiac disease in the United States. Am J Gastroenterol (2012) 4.77
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis (2008) 3.55
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46